Astonea Labs Ltd FY25 revenue rises to ₹97.52 crore from ₹80.19 crore
Key highlights
- Astonea Labs reported FY25 revenue of ₹97.52 crore, compared with ₹80.19 crore in the previous year.
- FY25 profit after tax rose to ₹5.35 crore from ₹4.07 crore, while EPS increased to ₹6.94 from ₹5.36.
- Astonea Labs listed on BSE SME on June 3, 2025, following an IPO of 27.90 lakh shares.
- The IPO was priced at ₹128 to ₹135 per share and had an issue size of up to ₹37.67 crore.
powered by IRIS

Astonea Labs Ltd reported FY25 revenue of ₹97.52 crore, up from ₹80.19 crore a year earlier, while profit after tax rose to ₹5.35 crore from ₹4.07 crore. The performance preceded its June 2025 BSE SME listing and offers a financial reference point for investors assessing its pharmaceutical and cosmetics manufacturing business.
Know Astonea Labs inside out
Results, valuation, peers and who's buying, in one view.
What did Astonea Labs report for FY25?
Astonea Labs reported a ₹17.33 crore increase in revenue for FY25, with revenue rising to ₹97.52 crore from ₹80.19 crore in the previous year. Profit after tax increased by ₹1.28 crore to ₹5.35 crore. Basic and diluted earnings per share were ₹6.94, compared with ₹5.36 in the preceding year.
The financial data points to higher revenue and profit in the year before the company's public-market debut. The figures were included in an investor feed that also noted that the company had 77.21 lakh equity shares of face value ₹10 each at the end of FY25, compared with 76 lakh shares in the prior year.
The available FY25 information also lists contingent liabilities of ₹8.42 crore. Borrowings and contingent liabilities are relevant alongside reported profit because they provide context on the company's funding and financial obligations. The supplied information does not provide a like-for-like prior-year comparison for these balance-sheet items.
How did Astonea Labs reach the BSE SME market?
Astonea Labs completed its initial public offering in May 2025 and listed its equity shares on the BSE SME platform on June 3, 2025. The issue opened on May 27 and closed on May 29, with the company offering 27.90 lakh shares at a price band of ₹128 to ₹135 per share.
At the upper end of the price band, the issue size was ₹37.67 crore. The IPO lot size was 1,000 shares, meaning the application amount at the lower price band was ₹1.28 lakh. The shares were credited to successful applicants' demat accounts on June 2, according to the stated IPO timetable.
The company's share capital changed before the listing. It allotted 1.21 lakh shares through a private placement at ₹100 per share on April 22, 2025. The investor feed stated that Managing Director Ashish Gulati held 74.43 lakh shares, or 96.40% of the equity, as of March 31, 2025.
What products and markets does Astonea Labs serve?
Astonea Labs operates as a contract manufacturer for pharmaceutical and cosmetic products for domestic and international customers. Its pharmaceutical portfolio includes antibiotics, anti-cold medicines, antihistamines, and products associated with diabetes, cardiovascular conditions, gynaecological needs and infections.
The company also manufactures personal-care products for skin, dental and hair care. These are offered in formats including creams, gels, serums, oils, ointments and lotions. Alongside third-party manufacturing, Astonea Labs markets its own brands, Glow Up and Regero, in India, and has identified Avicel as an upcoming brand.
Its disclosed overseas markets include Iraq and Yemen. Astonea Labs also trades in packaging and raw materials connected to its pharmaceutical and cosmetics activities. This combination of contract manufacturing, owned brands, exports and related trading activities forms the operating context for its FY25 revenue.
Got a follow-up? Ask IRIS
How does Astonea Labs plan to use its IPO proceeds?
Astonea Labs identified several uses for the IPO proceeds, including registration expenses in Bolivia, South America, and machinery for an ointment plant at its existing Haripur factory in Panchkula district, Haryana. The proposed plant is intended to operate in line with USFDA guidelines for export purposes.
The company also listed advertising, marketing and brand building, hardware and software procurement, working-capital requirements and general corporate purposes among the uses of funds. These plans cover both manufacturing capacity and commercial activity, including the development of its branded offerings.
The stated proceeds plan is important because the company operates in product categories where manufacturing capabilities, regulatory requirements, working capital and market access can all influence operations. The supplied information does not state the amount allocated to each individual use, so the relative size of these planned investments cannot be determined from the available material.
What do the FY25 figures mean for Astonea Labs investors?
Astonea Labs entered the public market after reporting higher FY25 revenue, profit after tax and earnings per share. Revenue increased by about 21.6% from the previous year, while profit after tax increased by about 31.5%, based on the stated figures. These reported changes establish the financial base immediately preceding the IPO and BSE SME listing.
For investors, the data also highlights the need to assess growth with the company's capital structure and stated funding needs. Long-term borrowings of ₹19.90 crore and short-term borrowings of ₹31.67 crore were reported for FY25, while contingent liabilities stood at ₹8.42 crore. The company's subsequent financial results and exchange filings will be relevant for tracking how its listed-market plans translate into reported operations.
Astonea Labs' business spans pharmaceutical formulations, cosmetics, own brands and export markets. Its future disclosures may therefore provide investors with information on the contribution of these different activities, although the supplied material does not provide a segment-wise revenue split or customer concentration details.
Conclusion
Astonea Labs reported FY25 revenue of ₹97.52 crore and profit after tax of ₹5.35 crore before raising up to ₹37.67 crore through its BSE SME IPO. The company's financial performance, borrowings and broad manufacturing portfolio are the main disclosed indicators for evaluating its position at the time it became publicly listed.
Investors can watch the company's periodic BSE filings, including its half-yearly and annual financial results, for updates on revenue, profitability, borrowings and the disclosed IPO objectives. The stated uses of funds, particularly the proposed ointment plant, Bolivia registration and working-capital funding, remain the key operational items identified by the company.


